Across TCGA pan-cancer cohorts, STYX Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STYX data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher STYX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STYX expression acts as an unfavorable survival marker.

COAD, CESC, and UCEC are the cancer types where STYX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.111	0.871	<.001	18	view →
CESC	DFS	Median	II,III,IV	0.193	0.705	.045	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: STYX tumor-vs-normal RNA expression · all STYX data types